Detalhe da pesquisa
1.
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 18(2): 192-201, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28094194
2.
Postischemic Administration of IL-1α Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke.
Circulation
; 142(2): 187-189, 2020 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32658615
3.
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
Invest New Drugs
; 33(3): 621-31, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25822109
4.
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Lancet Oncol
; 15(6): 656-66, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24746841
5.
IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19.
J Innate Immun
; 14(6): 643-656, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35545011
6.
Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.
Proc Natl Acad Sci U S A
; 105(46): 17908-12, 2008 Nov 18.
Artigo
Inglês
| MEDLINE | ID: mdl-19001265
7.
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
J Invest Dermatol
; 140(8): 1538-1545.e2, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32004568
8.
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.
Oncoimmunology
; 8(3): 1551651, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30723583
9.
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
J Invest Dermatol
; 138(4): 795-801, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29129600
10.
A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia.
PLoS One
; 13(1): e0190537, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29364906
11.
Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point.
Clin Ther
; 39(11): 2135-2145, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-29079389